RETRACTED: Molecular and therapeutic effect of CRISPR in treating cancer (Retracted article. See vol. 42, 2025)

被引:7
作者
Rodrigo, Sawani [1 ]
Senasinghe, Kaveesha [1 ]
Quazi, Sameer [2 ,3 ,4 ,5 ]
机构
[1] Univ Colombo, Fac Med, Human Genet Unit, Colombo, Sri Lanka
[2] GenLab Biosolut Pvt Ltd, Bengaluru 560043, Karnataka, India
[3] Anglia Ruskin Univ, Sch Life Sci, Dept Biomed Sci, Cambridge, England
[4] Univ Manchester, Sch Hlth Sci, Manchester, England
[5] ITMO Univ, SCAMT Inst, St Petersburg, Russia
关键词
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR); Chimeric Antigen Receptor (CAR) T cell therapy; Cancer; Immunotherapy; Gene therapy; Gene editing; CHIMERIC ANTIGEN RECEPTOR; T-CELL THERAPY; CAR; GENE; DISRUPTION; AUTOLEUCEL; RESPONSES; PROMOTES; ADULTS; SCFV;
D O I
10.1007/s12032-022-01930-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cancer has become one of the common causes of mortality around the globe due to mutations in the genome which allows rapid growth of cells uncontrollably without repairing DNA errors. Cancers could arise due alterations in DNA repair mechanisms (errors in mismatch repair genes), activation of oncogenes and inactivation of tumor suppressor genes. Each cancer type is different and each individual has a unique genetic change which leads them to cancer. Studying genetic and epigenetic alterations in the genome leads to understanding the underlying features. CAR T therapy over other immunotherapies such as monoclonal antibodies, immune checkpoint inhibitors, cancer vaccines and adoptive cell therapies has been widely used to treat cancer in recent days and gene editing has now become one of the promising treatments for many genetic diseases. This tool allows scientists to change the genome by adding, removing or altering genetic material of an organism. Due to advance in genetics and novel molecular techniques such as CRISPR, TALEN these genes can be edited in such a way that their original function could be replaced which in turn improved the treatment possibilities and can be used against malignancies and even cure cancer in future along with CAR T cell therapy due to the specific recognition and attacking of tumor.
引用
收藏
页数:18
相关论文
共 155 条
[1]   A Comprehensive Review of Recent Advancements in Cancer Immunotherapy and Generation of CAR T Cell by CRISPR-Cas9 [J].
Al Saber, Md. ;
Biswas, Partha ;
Dey, Dipta ;
Abu Kaium, Md. ;
Islam, Md. Aminul ;
Tripty, Miss Ismoth Ara ;
Rahman, MD. Hasanur ;
Rahaman, Tanjim Ishraq ;
Biswas, Md. Yeaman ;
Paul, Priyanka ;
Rahman, Md. Ataur ;
Hasan, Md. Nazmul ;
Kim, Bonglee .
PROCESSES, 2022, 10 (01)
[2]   CRISPR/Cas9-mediated TGFβRII disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells in vitro [J].
Alishah, Khadijeh ;
Birtel, Matthias ;
Masoumi, Elham ;
Jafarzadeh, Leila ;
Mirzaee, Hamid Reza ;
Hadjati, Jamshid ;
Voss, Ralf-Holger ;
Diken, Mustafa ;
Asad, Sedighe .
JOURNAL OF TRANSLATIONAL MEDICINE, 2021, 19 (01)
[3]   IL15 Enhances CAR-T Cell Antitumor Activity by Reducing mTORC1 Activity and Preserving Their Stem Cell Memory Phenotype [J].
Alizadeh, Darya ;
Wong, Robyn A. ;
Yang, Xin ;
Wang, Dongrui ;
Pecoraro, Joseph R. ;
Kuo, Cheng-Fu ;
Aguilar, Brenda ;
Qi, Yue ;
Ann, David K. ;
Starr, Renate ;
Urak, Ryan ;
Wang, Xiuli ;
Forman, Stephen J. ;
Brown, Christine E. .
CANCER IMMUNOLOGY RESEARCH, 2019, 7 (05) :759-772
[4]   CD73-Generated Adenosine: Orchestrating the Tumor-Stroma Interplay to Promote Cancer Growth [J].
Allard, Bertrand ;
Turcotte, Martin ;
Stagg, John .
JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY, 2012,
[5]   Shaping up the membrane: diacylglycerol coordinates spatial orientation of signaling [J].
Almena, Maria ;
Merida, Isabel .
TRENDS IN BIOCHEMICAL SCIENCES, 2011, 36 (11) :593-603
[6]   Brexucabtagene Autoleucel: A Novel Chimeric Antigen Receptor T-cell Therapy for the Treatment of Mantle Cell Lymphoma [J].
Anderson, Mary Kate ;
Torosyan, Annie ;
Halford, Zachery .
ANNALS OF PHARMACOTHERAPY, 2022, 56 (05) :609-619
[7]   Advances in CAR-T Cell Genetic Engineering Strategies to Overcome Hurdles in Solid Tumors Treatment [J].
Andrea, Alain E. ;
Chiron, Andrada ;
Mallah, Sarah ;
Bessoles, Stephanie ;
Sarrabayrouse, Guillaume ;
Hacein-Bey-Abina, Salima .
FRONTIERS IN IMMUNOLOGY, 2022, 13
[8]   Search-and-replace genome editing without double-strand breaks or donor DNA [J].
Anzalone, Andrew V. ;
Randolph, Peyton B. ;
Davis, Jessie R. ;
Sousa, Alexander A. ;
Koblan, Luke W. ;
Levy, Jonathan M. ;
Chen, Peter J. ;
Wilson, Christopher ;
Newby, Gregory A. ;
Raguram, Aditya ;
Liu, David R. .
NATURE, 2019, 576 (7785) :149-+
[9]   CRISPR/Cas: From Tumor Gene Editing to T Cell-Based Immunotherapy of Cancer [J].
Azangou-Khyavy, Mohammadreza ;
Ghasemi, Mobina ;
Khanali, Javad ;
Boroomand-Saboor, Melika ;
Jamalkhah, Monire ;
Soleimani, Masoud ;
Kiani, Jafar .
FRONTIERS IN IMMUNOLOGY, 2020, 11
[10]   Cost-Effectiveness of Brexucabtagene Autoleucel versus Best Supportive Care for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma following Treatment with a Bruton's Tyrosine Kinase Inhibitor in Canada [J].
Ball, Graeme ;
Lemieux, Christopher ;
Cameron, David ;
Seftel, Matthew D. .
CURRENT ONCOLOGY, 2022, 29 (03) :2021-2045